These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 26073262)

  • 1. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial.
    Preyer O; Umek W; Laml T; Bjelic-Radisic V; Gabriel B; Mittlboeck M; Hanzal E
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():51-6. PubMed ID: 26073262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS).
    Martin-Garcia M; Crampton J
    Physiotherapy; 2019 Dec; 105(4):469-475. PubMed ID: 30862384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study.
    Vecchioli-Scaldazza C; Morosetti C; Berouz A; Giannubilo W; Ferrara V
    Gynecol Obstet Invest; 2013; 75(4):230-4. PubMed ID: 23548260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review.
    Moossdorff-Steinhauser HF; Berghmans B
    Neurourol Urodyn; 2013 Mar; 32(3):206-14. PubMed ID: 22907807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
    Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
    J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcutaneous posterior tibial nerve stimulation versus extended release oxybutynin in overactive bladder patients. A prospective randomized trial.
    Manríquez V; Guzmán R; Naser M; Aguilera A; Narvaez S; Castro A; Swift S; Digesu GA
    Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():6-10. PubMed ID: 26645117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder.
    Chen HW; Bercik RS; Werner EF; Thung SF
    J Urol; 2012 Jan; 187(1):178-84. PubMed ID: 22100006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.
    Peters KM; Carrico DJ; Wooldridge LS; Miller CJ; MacDiarmid SA
    J Urol; 2013 Jun; 189(6):2194-201. PubMed ID: 23219541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes in the setting of a randomized control trial on the efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome.
    Ramírez-García I; Kauffmann S; Blanco-Ratto L; Carralero-Martínez A; Sánchez E
    Neurourol Urodyn; 2021 Jan; 40(1):295-302. PubMed ID: 33118624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.
    Pushkar DY; Kasyan GR; Kolontarev KB; Sharvadze GG; Mukhametshina EI
    Neurourol Urodyn; 2019 Jun; 38(5):1313-1321. PubMed ID: 30888691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: A prospective randomised controlled trial.
    Sonmez R; Yildiz N; Alkan H
    Ann Phys Rehabil Med; 2022 Jan; 65(1):101486. PubMed ID: 33429090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder.
    Salatzki J; Liechti MD; Spanudakis E; Gonzales G; Baldwin J; Haslam C; Pakzad M; Panicker JN
    BJU Int; 2019 May; 123(5A):E20-E28. PubMed ID: 30552801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months.
    Vecchioli-Scaldazza C; Morosetti C
    Int Braz J Urol; 2018; 44(1):102-108. PubMed ID: 29064651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study.
    Peters KM; Carrico DJ; MacDiarmid SA; Wooldridge LS; Khan AU; McCoy CE; Franco N; Bennett JB
    Neurourol Urodyn; 2013 Jan; 32(1):24-9. PubMed ID: 22674493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-inferior and more feasible transcutaneous tibial nerve stimulation in treating overactive bladder: A systematic review and meta-analysis.
    Alomari MS; Abdulhamid AS; Ghaddaf AA; Alshareef KM; Haneef AK; AlQuhaibi MS; Banjar RA
    Int J Urol; 2022 Oct; 29(10):1170-1180. PubMed ID: 35711082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.